Lys466

Site Information
LRRKRMEkMAEQQAV SwissProt Entrez-Gene
Blast this site against: NCBI SwissProt PDB
Site Group ID: 466666

In vivo Characterization
Methods used to characterize site in vivo:	mass spectrometry ( 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , 10 , 11 , 12 )
Disease tissue studied:	liver cancer ( 11 , 12 ) , hepatocellular carcinoma ( 11 , 12 ) , lung cancer ( 1 ) , non-small cell lung cancer ( 1 ) , non-small cell lung adenocarcinoma ( 1 )
Relevant cell line - cell type - tissue:	HCC78 (pulmonary) ( 2 , 3 ) , HCC827 (pulmonary) ( 1 ) , HepG2 (hepatic) ( 7 , 8 , 11 , 12 ) , NCI-H3255 (pulmonary) ( 5 , 6 ) , OCI/AML2 (myeloid) ( 9 ) , OCI/AML3 (myeloid) ( 10 ) , SW48 (intestinal) ( 4 )

References
1	Possemato A (2006) CST Curation Set: 1807; Year: 2006; Biosample/Treatment: cell line, HCC827/serum starved; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Curated Info
2	Possemato A (2006) CST Curation Set: 1808; Year: 2006; Biosample/Treatment: cell line, HCC78/serum starved; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Curated Info
3	Guo A (2006) CST Curation Set: 1600; Year: 2006; Biosample/Treatment: cell line, HCC78/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine Antibody Cat#: 9441 Curated Info
4	Li Y (2006) CST Curation Set: 1564; Year: 2006; Biosample/Treatment: cell line, SW48/untreated; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine Antibody Cat#: 9441 Curated Info
5	Guo A (2006) CST Curation Set: 1208; Year: 2006; Biosample/Treatment: cell line, NCI-H3255/-; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine Antibody Cat#: 9441 Curated Info
6	Guo A (2006) CST Curation Set: 1209; Year: 2006; Biosample/Treatment: cell line, NCI-H3255/-; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine Antibody Cat#: 9441 Curated Info
7	Mitchell J (2005) CST Curation Set: 1018; Year: 2005; Biosample/Treatment: cell line, HepG2/-; Disease: hepatocellular carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Curated Info
8	Mitchell J (2005) CST Curation Set: 1019; Year: 2005; Biosample/Treatment: cell line, HepG2/TSA &'\|\|' nicotinamide; Disease: hepatocellular carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Curated Info
9	Gu T (2005) CST Curation Set: 957; Year: 2005; Biosample/Treatment: cell line, OCI/AML2/-; Disease: acute myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine Antibody Cat#: 9441 Curated Info
10	Gu T (2005) CST Curation Set: 958; Year: 2005; Biosample/Treatment: cell line, OCI/AML3/-; Disease: acute myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine Antibody Cat#: 9441 Curated Info
11	Mitchell J (2005) CST Curation Set: 868; Year: 2005; Biosample/Treatment: cell line, HepG2/TSA; Disease: hepatocellular carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Curated Info
12	Mitchell J (2005) CST Curation Set: 870; Year: 2005; Biosample/Treatment: cell line, HepG2/TSA; Disease: hepatocellular carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Curated Info